Novartis said it expected core operating income to grow in the low double digits from a previous expectation of high-single-digit growth, lifted its sales guidance and confirmed its $15 billion share buyback.
Novartis said it expected core operating income to grow in the low double digits from a previous expectation of high-single-digit growth, lifted its sales guidance and confirmed its $15 billion share buyback.